☰

Aplex Bio AB

Scaling 100-plex diagnostics from research to regulated use

Industry
Molecular Diagnostics (Hyperplex PCR)
Headquarters
Solna, Stockholm, Sweden
Public information as of
February 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Aplex Bio AB's published strategy and is not endorsed by, or produced in cooperation with, Aplex Bio AB. Company website

Strategic priorities

Aplex Bio is a Swedish molecular-diagnostics company built around Nanopixels, its proprietary fluorescent nanoprobes, and Hyperplex PCR (hpPCR), an approach that decodes 100-plex molecular signals from conventional microscopes and thermocyclers. The company is incorporated in Solna at the Karolinska Science Park, founded in March 2020 as a spin-off from the Swedish life-sciences ecosystem, and is raising a 3 million EUR expansion round to scale Nanopixel synthesis, expand its laboratory footprint in 2026 and launch the Aplex Scanner.

The 2026 horizon is a transition from Research Use Only (RUO) kits to regulated in-vitro diagnostics. Under the EU In-Vitro Diagnostic Regulation (IVDR 2017/746) Notified Body oversight rises from roughly 20 percent of devices to 80 percent, and entry into the United States will require navigating 510(k) or Premarket Approval (PMA) pathways. Co-marketing agreements with diagnostic partners, signalled in 2025 pitch communications, depend on that regulatory transition completing on schedule.

Operationally, customer demand is already running ahead of internal manufacturing and processing capacity. Synthesis of Nanopixels is high-precision chemical hybridisation that today depends on laboratory bench work rather than a Manufacturing Execution System (MES), and samples for the service-project workflow are shipped to Stockholm for analysis, creating a logistics bottleneck that limits how many programs the company can run in parallel.

The hpPCR workflow is inherently data-heavy: each well produces 1 million-plus molecular counts across 4 to 6 fluorescence channels. Aplex Bio's own recruitment signals, including a master-thesis posting for AI-based image analysis, point to image-analysis algorithms that are functional but still need optimisation for speed, accuracy and hardware-agnostic performance across different microscope installations.

Challenges we see

  • Operations Manufacturing

    Scaling Nanopixel synthesis for a regulated product

    Nanopixel synthesis is high-precision chemical hybridisation using universal sequence labelling, and 2025 pitch communications stated that customer demand already exceeds internal manufacturing and processing capacity ahead of 2026 co-marketing agreements.

    Where synthesis still relies on laboratory bench work, every additional batch adds people, time and variability; moving from hand-driven synthesis to a documented, instrumented process is what makes the 2026 capacity step achievable and the output reproducible enough for an IVDR submission.

  • Digital Integration

    Closing the gap between microscopes and analysis software

    The transition from analog PCR to digital hpPCR produces 100-plus channels of image data per run, and scientists currently move data between microscopes and analysis workstations by hand. Public communications from the CEO describe the technology as running on commonly used laboratory equipment.

    Where data still travels between instruments and analysis software by file transfer, the transcript becomes the integration; instrument-level data capture with attached method, instrument and timestamp is what turns the workflow into one digital chain from sample to result.

  • Compliance Regulatory

    Producing IVDR and FDA evidence at the same time

    IVDR 2017/746 increases Notified Body oversight from roughly 20 percent to 80 percent of in-vitro diagnostic devices, and US entry requires 510(k) or PMA pathways. Aplex Bio's image-analysis software is likely to be classified as Software as a Medical Device (SaMD) under FDA's Laboratory Developed Tests (LDT) framework.

    Where the same diagnostic platform has to satisfy IVDR clinical-evidence requirements, FDA software-validation expectations and post-market surveillance in parallel, the validation evidence has to be designed once and reused across regimes rather than assembled separately for each submission.

  • Digital Operations

    Reducing image-analysis turnaround and false-positive rate

    Each well produces 1 million-plus molecular counts across 4 to 6 fluorescence channels. A publicly listed master-thesis opening for AI-based image analysis indicates that the algorithms in production today still need senior-level optimisation for speed and accuracy.

    Where the counting step is the throughput ceiling and the false-positive rate sets the diagnostic sensitivity, optimising the algorithm and instrument calibration together is what moves both the per-well run time and the lowest detectable variant allele frequency.

  • Digital Integration

    Keeping results reproducible across heterogeneous customer equipment

    Aplex Bio markets compatibility with conventional microscopes and thermocyclers, which exposes the software to variation in fluorescence filters, CCD sensor sensitivities and optical paths across customer installations.

    Where the same result has to come out of different instruments, the calibration layer becomes part of the product rather than a per-customer setup; building automated calibration and normalisation into the workflow is what keeps the assay claim portable across laboratories.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Instrumenting Nanopixel synthesis for IVDR-grade batch records

    Nanopixel synthesis is high-precision bench chemistry and 2025 pitch communications state that current demand exceeds internal manufacturing capacity. IVDR submissions require documented batch records and process evidence.

    Sensor instrumentation of synthesis reactors, an MES layer that captures batch genealogy, and a digital batch record that assembles process data alongside analytical results give Aplex Bio a per-batch evidence chain ready for a Notified Body review.

    • Stockholm Business Region, Aplex Bio pitch deck 2025
    • Aplex Bio Technology page

  2. Capturing microscope image data as data rather than files

    Image data from microscopes and thermocyclers currently moves between instruments and analysis software by manual file transfer, and a publicly listed master-thesis posting confirms the image-analysis stack is in active development.

    Connecting microscopes and thermocyclers through standardised protocols and writing the captured images straight into a sample-linked repository with method and instrument metadata attached gives the image-analysis pipeline the data context it needs and removes the manual transcript step.

    • Aplex Bio Technology page
    • Master thesis — AI based Image Analysis, Aplex Bio, Jobylon

  3. Producing reusable validation evidence across IVDR and FDA

    IVDR submissions and FDA 510(k) or PMA pathways each require their own validation evidence, and the company's fully automated analysis software will likely be regulated as Software as a Medical Device.

    A validation framework that generates IQ/OQ/PQ evidence once and reuses it across the IVDR technical file, the FDA submission and ongoing post-market surveillance cuts duplicate validation work and keeps the evidence current as the software evolves.

    • EU IVDR 2017/746 implementation analysis
    • Aplex Bio Technology page

  4. Building hardware-agnostic calibration into the analysis pipeline

    Aplex Bio's technology runs on commonly available laboratory equipment, which means results have to be reproducible across different fluorescence filters, CCD sensor sensitivities and microscope brands at customer sites.

    An automated calibration and normalisation layer that turns raw image data from different instruments into a single comparable output lets the company keep the hardware-agnostic value proposition while holding the result within a defined specification.

    • Aplex Bio Technology page
    • Master thesis — AI based Image Analysis, Aplex Bio, Jobylon

  5. Carrying chain of custody into forensic and clinical markets

    The company is opening forensic-science use cases (ISFG 2024 presentation) and entering regulated clinical diagnostics, both of which require rigorous chain-of-custody and data-integrity controls on image data and results.

    Identity-based access, signed audit trails and tamper-evident result records built into the platform from day one let Aplex Bio carry forensic-grade evidence into clinical and regulated-IVD deployments without a separate infrastructure project.

    • Hyperplex PCR to be presented at ISFG 2024, Aplex Bio News
    • Aplex Bio News page

What we'd propose

  • Digital CDMO

    Synthesis-line instrumentation and digital batch records

    We connect synthesis reactors, environmental sensors and analytical instruments into one time-series model and assemble a per-batch digital record that captures process data, analytical results and genealogy, giving Aplex Bio an IVDR-ready evidence chain from the synthesis bench.

    • Reactor and environment instrumentation

      Reading the synthesis as it runs

      Install temperature, pH, dosing and environmental sensors on synthesis reactors and stream their values through OPC UA (Open Platform Communications Unified Architecture) or MQTT so the synthesis process becomes a documented time series rather than a written-up batch.

    • MES layer with batch genealogy

      One batch record across stations

      Implement a Manufacturing Execution System that tracks raw materials, intermediate stages and finished reagents with their lot relationships, so each released kit can be traced back to the synthesis run, the operators and the equipment used.

    • IVDR-aligned digital batch record

      Evidence assembled as you go

      Write monitored parameters and analytical results into a per-batch record with audit-trail handling aligned to IVDR expectations, so a Notified Body review reads the evidence straight out of the system rather than from a reconstructed dossier.

    • Batch evidence is produced by the line rather than compiled for review.
    • Capacity increases arrive with the IVDR documentation already attached.
    • Each released kit carries a complete genealogy from synthesis to fill.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Microscope-to-analysis data pipeline

    We connect Aplex Bio's microscopes and thermocyclers through a vendor-neutral data layer and route captured images straight into the analysis pipeline with method, instrument and timestamp metadata attached, removing the manual transcript step.

    • Microscope and thermocycler integration

      Images captured at source

      Connect the microscopes and thermocyclers in use across the service-project workflow so images leave the instrument with instrument identity, method version and acquisition parameters attached, instead of being exported and re-keyed at the workstation.

    • Sample-linked image repository

      One record per sample

      Store captured images in a repository linked to the originating sample, plate and run, so the downstream analysis pipeline can pull the full set of inputs for a sample and the audit trail traces back to the well and the operator who started the run.

    • Automated handover to the analysis pipeline

      No manual file transfer

      Trigger the image-analysis workflow automatically when the run finishes, so the scientist sees a result instead of a queue of files to move, and so the pipeline operates on a defined input contract rather than whatever the operator remembered to copy across.

    • Scientists stop spending time moving files and re-keying sample IDs.
    • Image-analysis runs on a complete, annotated input set every time.
    • Customer-facing service projects scale without a parallel increase in data-handling effort.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Reusable validation framework for IVDR and FDA

    We design and implement a Computer System Validation framework that generates IQ/OQ/PQ evidence once and reuses it across the IVDR technical file, the FDA 510(k) or PMA submission, and the post-market surveillance update cycle, with the image-analysis software treated as Software as a Medical Device.

    • IVDR-aligned validation protocol library

      One protocol library, multiple regimes

      Define a library of validation protocols covering installation, operational and performance qualification that maps to both IVDR expectations and FDA 21 CFR Part 11, so a single test run can satisfy both review regimes without bespoke rewrites.

    • Automated evidence generation

      Evidence produced by execution

      Drive validation runs from the framework itself so the test scripts, results and signed approvals are produced as system output rather than manually compiled, and so the evidence chain is reproducible when a Notified Body or FDA reviewer asks to see how a result was obtained.

    • Post-market change control

      Re-validation scoped by impact

      Connect the validation framework to the software change-control process so a release notes which validation scripts have to be re-run and which remain valid, keeping the evidence current without repeating every test on every change.

    • Validation work is done once and reused across regulatory regimes.
    • Software updates trigger re-validation only where the change actually affects the validated behaviour.
    • A Notified Body or FDA review reads evidence straight out of the system.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Hardware-agnostic calibration and normalisation layer

    We build a calibration and normalisation layer that turns raw image data from heterogeneous microscopes into a single comparable output, so the hpPCR result stays within specification across customer installations without per-site setup work.

    • Automated calibration routines

      Per-instrument calibration, automated

      Generate calibration routines that capture the fluorescence-filter and CCD-sensor characteristics of each microscope at customer sites and run those routines as part of the standard workflow, so instrument-specific behaviour is captured in software rather than relying on operator judgement.

    • Cross-instrument normalisation

      Comparable results across sites

      Normalise images to a common reference frame so the same hpPCR panel returns the same molecular counts whether it ran on one microscope brand or another, and so a multi-site study can be analysed without per-site reconciliation steps.

    • Quality-watchdog flags

      Out-of-spec instruments flagged early

      Continuously check that each instrument is still inside its calibration envelope and flag drift before it becomes a customer-visible discrepancy, so the service-project team is told when an instrument needs attention instead of after a customer's results have already shifted.

    • The hardware-agnostic value proposition holds up at customer sites.
    • Drift is caught at the instrument rather than at the customer's complaint.
    • Multi-site studies can be analysed as one data set rather than as a reconciliation project.

    We've done this before

    See how we do Digital Lab
  • Agents

    AI agents for IVDR and FDA document work

    Narrow, reviewable agents that take the repetitive part of Aplex Bio's regulatory document work: drafting validation summaries from system records, checking an IVDR technical-file section or a 510(k) module against its template before review, and finding every controlled document a standard or method change affects. A named person approves every output.

    • Drafting from system records

      First drafts from real evidence

      Generate the first draft of an IVDR technical-file section, an FDA 510(k) module or a Software as a Medical Device lifecycle document directly from the underlying validation, batch and change-control records, so the author edits and judges rather than assembles the document from scratch.

    • Template and completeness checking

      Gaps found before review

      Check a submitted section against its IVDR or FDA template and the company's own checklist, returning missing or inconsistent sections before the document enters the human review queue, so reviewers spend time on judgement rather than on finding gaps.

    • Change-impact search across the document set

      Which documents a change touches

      When a standard, a method or a kit specification changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one and the re-validation pipeline is triggered for the right records.

    • Review queues move faster because documents arrive complete.
    • The scope of a standard or method change is established by search rather than by recollection.
    • Every output is traceable to the source records it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Aplex Bio AB's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Synthesis process data 28 → 78
Nanopixel synthesis is high-precision bench chemistry, with 2025 pitch communications stating that demand exceeds internal capacity. The route to IVDR-grade batch evidence runs through instrumenting the bench and assembling the per-batch record as the synthesis runs.
Equipment to analysis connectivity 30 → 78
Microscope and thermocycler data currently moves to the analysis workstation by manual file transfer, which sits directly in the throughput path of the service-project workflow. The connectivity layer is the immediate-term opportunity rather than a longer-term plan.
Regulatory validation infrastructure 32 → 82
The company is RUO today and moving to IVDR plus FDA, with the image-analysis software likely classified as Software as a Medical Device. A reusable validation framework is a near-term prerequisite for both regimes.
Algorithm maturity 42 → 85
Image-analysis algorithms are functional and a publicly listed master-thesis opening indicates active optimisation work. The route from 1 million-plus molecular counts per well to a regulated diagnostic result runs through senior-level algorithm review and validation.
Hardware-agnostic calibration 35 → 80
The technology is marketed as running on commonly available laboratory equipment, which exposes the result to per-instrument variation. Calibration routines and cross-instrument normalisation are what keep the assay claim portable.
Chain-of-custody and data integrity 25 → 75
Forensic and regulated-IVD use cases both require rigorous chain-of-custody evidence on image data and results, and the platform's audit-trail posture is at an early stage. Identity-based access and signed records are the foundation for forensic and clinical market entry.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of February 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Aplex Bio AB, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].